Lyra Therapeutics (LYRA) Enterprise Value (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Enterprise Value of -$15.9 million in Q4 2025, up 28.09% on a QoQ basis from -$22.1 million in Q3 2025, and up 60.83% YoY from -$9.9 million in Q4 2024.
Lyra Therapeutics (LYRA) Enterprise Value (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Enterprise Value for 7 consecutive years, with -$15.9 million the latest figure, recorded in Q4 2025.
- Enterprise Value for Q4 2025 came in at -$15.9 million, up 60.83% year-over-year; the trailing twelve-month figure through Dec 2025 was -$15.9 million (up 60.83% YoY), and the FY2025 annual result was -$15.9 million, up 60.83% from the prior year.
- Enterprise Value for Q4 2025 stood at -$15.9 million, up from -$22.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$15.9 million in Q4 2025, with the low at -$122.4 million in Q2 2022.
- A 5-year average of -$71.3 million and a median of -$74.0 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value sank 146.78% in 2023 and surged 61.04% in 2024, its largest moves.
- Lyra Therapeutics' Enterprise Value stood at -$46.1 million in 2021, then sank by 115.48% to -$99.3 million in 2022, then declined by 4.89% to -$104.1 million in 2023, then surged by 61.04% to -$40.6 million in 2024, then jumped by 60.83% to -$15.9 million in 2025.
- The last three Enterprise Value figures came in at -$15.9 million (Q4 2025), -$22.1 million (Q3 2025), and -$40.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 2.12 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.89 Mn |
| Sep 30, 2025 | -22.10 Mn |
| Dec 31, 2024 | -40.58 Mn |
| Sep 30, 2024 | -53.62 Mn |
| Jun 30, 2024 | -69.50 Mn |
| Mar 31, 2024 | -89.11 Mn |
| Dec 31, 2023 | -104.15 Mn |
| Sep 30, 2023 | -103.94 Mn |
| Jun 30, 2023 | -78.42 Mn |
| Mar 31, 2023 | -84.11 Mn |
| Dec 31, 2022 | -99.29 Mn |
| Sep 30, 2022 | -111.31 Mn |
| Jun 30, 2022 | -122.42 Mn |
| Mar 31, 2022 | -34.08 Mn |
| Dec 31, 2021 | -46.08 Mn |
| Mar 31, 2021 | -66.11 Mn |
| Dec 31, 2020 | -74.92 Mn |
| Jun 30, 2020 | -86.60 Mn |
| Mar 31, 2020 | -35.25 Mn |
| Dec 31, 2019 | -9.81 Mn |